PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsMethoxsalen
Methoxsalen
Methoxsalen, Oxsoralen-ultra, Uvadex (methoxsalen) is a small molecule pharmaceutical. Methoxsalen was first approved as 8-mop on 1982-01-01. It is used to treat mycosis fungoides, psoriasis, and vitiligo in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
hemic and lymphatic diseasesD006425
skin and connective tissue diseasesD017437
immune system diseasesD007154
Trade Name
FDA
EMA
Methoxsalen, Oxsoralen-ultra, Uvadex (discontinued: Methoxsalen, Oxsoralen)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Methoxsalen
Tradename
Company
Number
Date
Products
OXSORALEN-ULTRABausch Health CompaniesN-019600 RX1986-10-30
1 products, RLD, RS
UVADEXMallinckrodtN-020969 RX1999-02-25
1 products, RLD, RS
Show 2 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
methoxsalenANDA2025-03-11
uvadexNew Drug Application2024-12-16
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
D: Dermatologicals
D05: Antipsoriatics
D05A: Antipsoriatics for topical use
D05AD: Psoralens for topical use
D05AD02: Methoxsalen
D05B: Antipsoriatics for systemic use
D05BA: Psoralens for systemic use
D05BA02: Methoxsalen
HCPCS
No data
Clinical
Clinical Trials
67 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MycosesD009181B35-B49112
T-cell lymphomaD016399112
Mycosis fungoidesD009182C84.0112
T-cell lymphoma cutaneousD016410C84.A112
LymphomaD008223C85.911
T-cell lymphoma peripheralD01641111
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Graft vs host diseaseD006086D89.812316
Bronchiolitis obliterans syndromeD000092122D89.8111113
SyndromeD013577112
Bronchiolitis obliteransD001989EFO_0007183J44.8111
BronchiolitisD00198811
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SclerosisD012598112
Sezary syndromeD012751C84.1112
Crohn diseaseD003424EFO_0000384K5011
Rheumatoid arthritisD001172EFO_0000685M06.911
ArthritisD001168EFO_0005856M05-M1411
Systemic sclerodermaD012595EFO_0000717M3411
Diffuse sclerodermaD045743EFO_000040411
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LeukemiaD007938C9511
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Graft rejectionD00608411
Multiple sclerosisD009103EFO_0003885G3511
Neoplasm metastasisD009362EFO_000970811
Chronic progressive multiple sclerosisD020528EFO_000384011
Kidney transplantationD01603011
Hiv infectionsD015658EFO_0000764B2011
Aids-related complexD000386EFO_0007137B2011
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameMethoxsalen
INN
Description
Methoxsalen is a member of the class of psoralens that is 7H-furo[3,2-g]chromen-7-one in which the 9 position is substituted by a methoxy group. It is a constituent of the fruits of Ammi majus. Like other psoralens, trioxsalen causes photosensitization of the skin. It is administered topically or orally in conjunction with UV-A for phototherapy treatment of vitiligo and severe psoriasis. It has a role as a dermatologic drug, an antineoplastic agent, a photosensitizing agent, a cross-linking reagent and a plant metabolite. It is a member of psoralens and an aromatic ether. It is functionally related to a psoralen.
Classification
Small molecule
Drug classanti-inflammatory agents (salicylic acid derivatives)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
COc1c2occc2cc2ccc(=O)oc12
Identifiers
PDB
CAS-ID298-81-7
RxCUI
ChEMBL IDCHEMBL416
ChEBI ID18358
PubChem CID4114
DrugBankDB00553
UNII ID
Target
No data
Variants
No data
Financial
Revenue by drug
$
£
No data
Estimated US medical usage
Methoxsalen
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 1,818 documents
View more details
Safety
Black-box Warning
Black-box warning for: Methoxsalen, Uvadex
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
681 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use